Core Insights - Boston Scientific (BSX) has been actively pursuing acquisitions to bolster its growth strategy, enhancing its core businesses and entering high-growth adjacent markets [1][5] - The company recently acquired Elutia's BioEnvelope business to prevent post-operative complications for devices like pacemakers and defibrillators, aiming to expand this technology globally [1] - The acquisition of Anrei Medical for approximately $182 million enhances BSX's Endoscopy portfolio, providing more treatment options for physicians [2] - Recent acquisitions, including SoniVie and Intera Oncology, have expanded BSX's offerings in Interventional Cardiology and oncology [3][4] - The acquisition of Bolt Medical aligns with the growth of intravascular lithotripsy therapy, complementing BSX's Cardiovascular portfolio [4] - In Q3 2025, acquisitions contributed 420 basis points to sales, resulting in 15.3% organic revenue growth, exceeding the company's guidance of 12%-14% [5][9] - BSX's stock has increased by 13.1% year-to-date, outperforming the industry growth of 4.9% [8] Acquisitions and Market Position - BSX's recent acquisitions have strengthened its CRM, Endoscopy, Interventional Cardiology, Oncology, and Electrophysiology portfolios [9] - The company has entered into a definitive agreement to acquire Nalu Medical, further enhancing its Neuromodulation division [5][9] - Competitors like Teleflex and GE Healthcare are also active in M&A, with Teleflex acquiring BIOTRONIK's Vascular Intervention business and GE Healthcare acquiring Intelerad for $2.3 billion [6][7] Financial Performance - BSX's valuation is currently high, with a forward five-year Price-to-Earnings (P/E) ratio of 29.57, above its median and industry average [10] - Earnings estimates for BSX are trending upward, with current estimates for the current quarter at $0.78 and for the next year at $3.45 [11][12]